Vericel (VCEL) Asset Writedowns and Impairment (2014 - 2026)

Vericel (VCEL) posted Asset Writedowns and Impairment of $152000.0 for Q2 2026, down 12.14% sequentially from $173000.0 in Q1 2026.

Analysis

Vericel (VCEL) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends

Vericel has reported Asset Writedowns and Impairment for 6 years, with the latest figure at $152000.0 in Q2 2026.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $152000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $325000.0 (up 38.89% YoY) and the FY2025 annual result came in at $1.0 million, changed N/A from the prior year.
Asset Writedowns and Impairment eased to $152000.0 in Q2 2026 per VCEL's latest filing, from $173000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $173000.0 in Q1 2026 and troughed at $152000.0 in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn

Historic Data

Download Data